My current research is focused on expanding the chemical toolbox for neural signaling and anti-inflammation/anti-oxidant pathways to help us understand the mechanism of action of the disease pathology associated with glaucomatous optic neuropathy, Alzheimer’s Diseases, Ischemic stroke, and angiogenesis. Our lab integrates medicinal chemistry, chemical biology, bio-engineering, and drug delivery using nanotechnology. We employ synthetic organic and organometallic chemistry to generate a small molecule library for low throughput as well as high throughput screening (target based as well as phenotypic). The ultimate goal of my lab is to produce novel therapeutic molecules which can be progressed to human clinical trials for these diseases.